The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Open accessAbstract
Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate. Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of >2 months. Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score ≤ −2.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months). Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score < −3.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of >2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T. P., Glüer, C., Grampp, S., Harris, S. T., Jergas, M. D., Lang, T., Lü, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 948
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 926
Research works printed but not linked: 4
- Melton, 1991, Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites, J Bone Miner Res, 6, S136
- Kendler, 2002, Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study, Osteoporos Int, 13, S32
- Palmisano, 2002, Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis, Osteoporos Int, 13, S36
- Kiel, 1995, Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures, J Bone Miner Res, 10, 518
Cited by
Sorted by citations
Items 901–999 of 999
New directions in osteoporosis therapy: Intravenous ibandronate and denosumab
Teng, G. G., Patkar, N. M., & Saag, K. G. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0021-2 · Cited by 2
Can high bone turnover markers identify osteopenic postmenopausal women at risk of future fracture?
Reid, D. M. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0560 · Cited by 2
Uses and misuses of statistics: The case of strontium ranelate and the number needed to treat
Pedrazzoni, M., Giusti, A., & Pioli, G. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03345397 · Cited by 2
Preventing and Treating Osteoporosis: Pharmacologic and Nonpharmacologic Approaches
Chavez, J. (2009) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2009.03.015 · Cited by 2
Once-monthly risedronate for postmenopausal osteoporosis
Becker, C., & Casadei, K. L. (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s3789 · Cited by 2
Brandi, M. L. (2008) · PubMed Central · Cited by 2
Prevention of Osteoporotic Fractures
Lewiecki, E. M. (2006) · Aging Health · doi:10.2217/1745509x.2.4.649 · Cited by 2
Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis
Ma, Z., Li, Y., Zhou, M., Huang, K., Hu, H., Liu, X., & Xu, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150203 · Cited by 2
Kumar, Y. S., Jain, A., Ashok, K., & Anangpuria, B. S. (2010) · International Journal of Pharmacy and Life Sciences · Cited by 2
Mitchell, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-25976-5_13 · Cited by 2
Sebastian, A. S., & Rihn, J. A. (2017) · Seminars in Spine Surgery · doi:10.1053/j.semss.2017.09.011 · Cited by 2
Second Colombian Consensus on the Management of Post-menopausal Osteoporosis: 2017 update
Orjuela, A. M., Olarte, Ó. R., Rueda-Plata, P. N., Escobar, F. S., Chalem, M., Reyes, M., González, A. R., Lozano, A. T., Talero, A. P., Rueda, C., et al. (2018) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2019.01.004 · Cited by 2
Effect of Bisphosphonates on Fracture Incidence in Young Adults With Low Bone Density
Choudhary, M., Maximous, M., Yang, S.-J., & Chock, B. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.06.007 · Cited by 2
Endocrinology of Bone and Growth Disorders
Farquharson, C., Stephen, L. A., & Wong, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00086-4 · Cited by 3
Ibandronate in the Management of Postmenopausal Osteoporosis
Reginster, J., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2354 · Cited by 2
Guglielmi, G., & Diacinti, D. (2008) · Springer eBooks · doi:10.1007/978-3-540-68604-0_8 · Cited by 2
Macías, J. G., & Olmos, J. M. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.04.003 · Cited by 2
Upmanyu, V., Sapra, L., & Srivastava, R. K. (2022) · Studies in natural products chemistry · doi:10.1016/b978-0-323-91250-1.00005-7 · Cited by 2
Simic-Pasalic, K., & Esther, S. Y. (2012) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh1212722s · Cited by 2
Current Therapies for Osteoporosis
Bayly, J. (2007) · Springer eBooks · doi:10.1007/978-1-84628-587-5_10 · Cited by 2
Single annual injectable treatment for postmenopausal osteoporosis
Chapurlat, R. D. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.5.583 · Cited by 2
Die Entwicklung der Bisphosphonate—ein Meilenstein in der Osteoporosetherapie
Faßbender, W. J., Stumpf, U. C., & Kurth, A. (2006) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-006-9002-x · Cited by 3
Faut-il dépister l’ostéoporose du sujet âgé ?
Blain, H. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.10.413 · Cited by 2
Lessons from osteoporosis clinical trials
Silverman, S. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.04.006 · Cited by 2
Metabolic Bone Disorders of the Spine
Unnanuntana, A., Miki, R. A., Gladnick, B. P., Sherman, P. J., Madore, G. R., & Lane, J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6726-9.00087-0 · Cited by 2
Bone mineral density as a surrogate biomarker for fracture risk reduction – Authors' reply
Black, D. M., Bouxsein, M., Bauer, D. C., & Eastell, R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30340-5 · Cited by 2
Ibandronate (Boniva): A New Oral Bisphosphonate
(2005) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000169604.68745.bc · Cited by 2
Miller, P. D., & Watts, N. B. (2013) · Wiley eBooks · doi:10.1002/9781118316290.ch9 · Cited by 2
Postoperative Bone Mineral Health Optimization in the Geriatric Patient
Kondapalli, A. V., & Walker, M. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-78969-5_11 · Cited by 1
Osteoporose na Medicina Geral e Familiar: Estaremos a Fazer o Necessário?
Teixeira, F. D. C., Serejo, R. D. F., & Araújo, F. (2022) · Gazeta Médica · doi:10.29315/gm.v9i2.584 · Cited by 1
The Place of Ibandronate in the Pharmacotherapy of Postmenopausal Osteoporosis
Skripnikova, I. A. (2024) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2024-20-8-18-24 · Cited by 1
Antiresorptive Therapy for Osteoporosis in Older Subjects
Sølling, A. S., Laursen, N. A., Harsløf, T., & Langdahl, B. L. (2025) · Gerontology · doi:10.1159/000544781 · Cited by 2
Maloney-Saxon, G. (2025) · Nursing · doi:10.1097/nsg.0000000000000179 · Cited by 1
Ploumis, A., Kefalas, A., Vasileiadis, G. I., Kougkouli, E., Markou, A., Dimakopoulos, G., Doulgeri, S., & Varvarousis, D. (2025) · Injury · doi:10.1016/j.injury.2025.112357 · Cited by 1
Rakuša, M., Leonardis, L., Koritnik, B., Janež, A., & Jensterle, M. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100253 · Cited by 1
January, S. E., Fester, K. A., Escamilla, J. E., & Cano, M. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70040 · Cited by 1
Drugs against osteoporosis in perimenopausal and postmenopausal women
Lv, H., Zhang, Y., Li, J., Jia, Q., Yu, Y., Tang, H., Chen, W., Yang, Y. S., Jiang, Q., & Chen, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1682333 · Cited by 1
Marchenkova, L., & Vasileva, V. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-384 · Cited by 1
Cho, Y. R., Byun, S., & Lee, H.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-28252-7 · Cited by 1
Huang, W., Chen, J., Zhou, Q., & Rezaei, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1750238 · Cited by 1
Dufault, S. M., Thompson, A. R., Lui, L., Ewing, S. G., Bouxsein, M., Eastell, R., & Black, D. M. (2026) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjag059 · Cited by 1
Zhou, Z., Yang, Q., Liu, L., Guo, W., Xu, F., Liu, Y., Li, X., Wu, Y., Zhou, N., Yao, H., et al. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45032 · Cited by 1
Wang, Y., Wang, X., Yu, G., Zhang, L., Xue, C., Gong, W., Luo, J., Lu, C., & Wang, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1886136 · Cited by 1
Moseley, K. F., & de Beur, S. M. J. (2010) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-374271-1.00059-9 · Cited by 1
Bonnick, S. L., & Lewis, L. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3625-6_9 · Cited by 1
Osteoporosebehandlung im höheren Lebensalter
Jaspers, C., & Lakomek, H. ‐. (2009) · Arthritis und Rheuma · doi:10.1055/s-0037-1620140 · Cited by 1
Controversia en relación con el uso de bifosfonatos en pacientes con enfermedad renal
Valencia, C. A. R., & Iglesias, G. M. (2009) · Cited by 1
Fardellone, P., Cortet, B., Legrand, É., Bresse, X., Bisot-Locard, S., Vigneron, A.-M., & Béresniak, A. (2010) · Revue du Rhumatisme · doi:10.1016/j.rhum.2009.11.003 · Cited by 1
Quarterly Intravenous Ibandronate for Postmenopausal Osteoporosis
Emkey, R. D. (2008) · Women s Health · doi:10.2217/17455057.4.3.219 · Cited by 1
Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Yang, R., & Liu, S. (2008) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/187221409787002958 · Cited by 1
Documenting the Use of Calcium Supplements with Oral Bisphosphonates
Nye, A. M., Hamrick, I., Rauch, A., Pound, M. W., & Shelton, P. S. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.31 · Cited by 1
Intravenous Ibandronate in the Treatment of Osteoporosis1
Croom, K. F., & Scott, L. J. (2006) · Drugs & Aging · doi:10.2165/00002512-200623120-00006 · Cited by 1
Stratégie au long cours du traitement de l'ostéoporose postménopausique
Rizzoli, R. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.09.003 · Cited by 1
Tratamiento de las osteoporosis
Henríquez, M. S., & Hernández, D. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)73245-x · Cited by 1
Ibandronate: A Review of its Vertebral and Nonvertebral Antifracture Efficacy
Amling, M., & Kurth, A. (2009) · Women s Health · doi:10.2217/whe.09.38 · Cited by 1
Adkins, J. (2008) · Drugs in Context · doi:10.7573/dic.212224 · Cited by 1
Osteoporose no climatério II: prevenção e tratamento
Fontes, T. M. P., de Araújo, L. F. B., & Soares, P. R. G. (2012) · Cited by 1
Medical Treatment of Age Related Osteoporosis
Wong, E. K. C., Kim, L. H.-Y., & Παπαϊωάννου, Α. (2016) · Springer eBooks · doi:10.1007/978-3-319-25976-5_12 · Cited by 1
DISORDERS OF CALCIUM METABOLISM AND BONE MINERALIZATION
Clarke, B. L., & Khosla, S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50043-3 · Cited by 1
Interventions to improve treatment of osteoporosis following fracture
Schafer, A. L., & Sellmeyer, D. E. (2008) · Journal of clinical outcomes management · Cited by 1
Ibrahim, I., Nazmy, W., Saad, A., & Abdel‐Hakeem, E. A. (2012) · Bulletin of Egyptian Society for Physiological Sciences · doi:10.21608/besps.2012.35506 · Cited by 1
Osteoporotic Vertebral Fractures
Telera, S. M., Raus, L., Pipola, V., Iure, F. D., & Gasbarrini, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-76555-2_9 · Cited by 1
Zini, M. (2011) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.1007/s13631-011-0016-x · Cited by 1
(2007) · Humana Press eBooks · doi:10.1007/978-1-59259-992-9_9 · Cited by 1
Kobayashi, T., Kaneko, M., & Narukawa, M. (2019) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479019833657 · Cited by 1
Saag, K. G. (2008) · Springer eBooks · doi:10.1007/978-0-387-68566-3_35 · Cited by 1
Rosen, C. J. (2012) · Goldman's Cecil Medicine · doi:10.1016/b978-1-4377-1604-7.00251-7 · Cited by 1
Impact assessment of ibandronic acid use in patients with postmenopausal osteoporosis
Shalina, M. A., & Yarmolinskaya, M. I. (2023) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush20232303192 · Cited by 1
Zhu, Y.-Y., Wei, H.-F., Li, S., Li, L., Wang, P., & Pan, H. (2025) · Journal of Orthopaedics · doi:10.1016/j.jor.2025.05.049 · Cited by 1
Condition Critical: Compliance and Persistence with Osteoporosis Medications
Gold, D. T. (2013) · Academic Press eBooks · Cited by 1
Drug-Induced Esophageal Injury
Namasivayam, V., & Murray, J. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3794-9_45 · Cited by 1
van der Sluijs, C. P. (2007) · Cited by 1
Tan, M. Z., Chionh, S. B., & Chandran, M. (2012) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.027.02.05 · Cited by 1
New Approaches to the Diagnosis and Treatment of Postmenopausal Osteoporosis
Kim, B. (2006) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2006.21.2.91 · Cited by 1
Pyadushkina, E., Герасимова, К. В., Goryainov, S., Omelyanovsky, V. V., Avksentyeva, M. V., & Сергеевич, К. И. (2012) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2012-771 · Cited by 1
Vouri, S. M., Álvarez, C. A., & Blaszczyk, A. T. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.04.001 · Cited by 1
Injectable Bisphosphonates for the Treatment of Osteoporosis
Reginster, J., Burlet, N., Close, P., & Bruyère, O. (2007) · Women s Health · doi:10.2217/17455057.3.6.719 · Cited by 1
Raskina, T. A., Averkieva, J., Raskina, T. A., & Averkieva, J. (2011) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2011-650 · Cited by 1
Shiraishi, A. (2014) · Folia Pharmacologica Japonica · doi:10.1254/fpj.143.302 · Cited by 1
The Clinical Role of Bone Density Scans in the Diagnosis and Treatment of Osteoporosis
Blake, G. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-459-9_4 · Cited by 1
Grygorieva, N. V. (2019) · PAIN JOINTS SPINE · doi:10.22141/2224-1507.9.1.2019.163057 · Cited by 2
Reid, D. M. (2011) · doi:10.1007/978-1-908517-10-4_7 · Cited by 1
Slovik, D. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-54947-9.00141-3 · Cited by 1
Nutritional and Pharmacological Aspects of Osteoporosis
Ontjes, D. A., & Anderson, J. J. B. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-385-5_22 · Cited by 1
Avances en el tratamiento de la osteoporosis. Estrategias de aplicaci?n pr?ctica
Macas, J. G., & Moral, J. A. R. (2007) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(07)74761-6 · Cited by 1
Ibandronate: is there an effect on nonvertebral fractures?
Kaštelan, D., Koršić, M., & Vlak, T. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0971-4 · Cited by 1
High-Dose Versus Low-Dose Ibandronate Decreases Risk of Clinical Fractures
Miller, E. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2029 · Cited by 1
Questioning the Accuracy of a Recent Review of Osteoporosis Medications
Kuhl, L. N., Ettinger, B., Rosen, C. J., & Col, N. F. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-6-200903170-00015 · Cited by 1
Screening Strategies for Treatment of Osteoporosis in Long‐Term Care Residents
Shil, A. B., & Greer, J. R. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12024 · Cited by 1
On redefining the relationship of the hot flash to the health of peri-and postmenopausal women
SHULMAN, L. P. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318181335c · Cited by 1
Ibandronate: a new perspective in the treatment of osteoporosis
Reginster, J. (2005) · Therapy · doi:10.1586/14750708.2.2.179 · Cited by 1
Nuevas estrategias terapéuticas en la osteoporosis
Carranza, F. H., & Guerra, G. (2007) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(07)71476-6 · Cited by 1
Bisphosphonate Therapy for the Treatment of Postmenopausal Osteoporosis
Devogelaer, J., Boutsen, Y., & Manicourt, D. H. (2005) · Aging Health · doi:10.2217/1745509x.1.3.459 · Cited by 1
Ibandronate: Once-Monthly and Intravenous Dosing Options for Osteoporosis Treatment
Emkey, R. D. (2006) · Women s Health · doi:10.2217/17455057.2.3.341 · Cited by 1
Evidence-based drug treatment of osteoporosis
Förster, K. K., & Peters, K. M. (2008) · Steinkopff eBooks · doi:10.1007/978-3-7985-1842-1_22 · Cited by 1
Interventions for Osteoporosis
Keating, F. S. J., & Stevenson, J. C. (2007) · Elsevier eBooks · doi:10.1016/b978-012369443-0/50035-1 · Cited by 1
Osteoporosis and metabolic bone disease
(2014) · Rheumatology · doi:10.1093/rheumatology/keu113 · Cited by 1
Diagnostik und Therapie der Osteoporose. Teil 2. Präventive und therapeutische Massnahmen
Meier, C., Seibel, M. J., & Kraenzlin, M. (2006) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2006.05939 · Cited by 1
(2008) · PubMed · Cited by 160
Self-citation
Metadata
- Authors
- Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & (BONE), F. T. O. I. O. V. F. T. I. N. A. A. E.
- Affiliations
- University of Washington (US)
- Center for Clinical Trials, Bergen, Norway
- Center for Clinical & Basic Research (DK)
- Creighton University (US)
- CECOR AS, Haugesund, Norway
- Oslo Department, Sentrum Røntgen Institut AS, Oslo, Norway
- Universitatsklinikum Benjamin Franklin, Berlin, Germany
- Leverkusen, Germany
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- Lyon 1 Université (FR)
- Corresponding author
- Chesnut, Charles H
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 19
- Issue
- 8
- Pages
- 1241-1249
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099054178
- Cited by
- 1,229
- References
- 42
- Citations by year
- 2026: 14 · 2025: 38 · 2024: 20 · 2023: 42 · 2022: 31 · 2021: 37 · 2020: 35 · 2019: 32 · 2018: 32 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 45 · 2013: 63 · 2012: 62
- FWCI
- 85.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- ibandronate, intermittent dosing, bisphosphonates, postmenopausal osteoporosis, vertebral fractures, fracture risk reduction, bone mineral density, bone turnover, height loss, drug safety, medication adherence, lumbar spine, hip bone density, antifracture efficacy, treatment discontinuation, adverse events
- MeSH terms
- Ibandronic Acid, Aged, Body Height, Bone and Bones, Diphosphonates, Double-Blind Method, Female, Femur, Humans, Lumbar Vertebrae, Middle Aged, Pelvic Bones, Prospective Studies, Risk Factors, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome, Patient Selection, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
